In the rapidly evolving landscape of oncology, Antibody-Drug Conjugates (ADCs) have emerged as one of the most promising classes of therapeutics. Often described as “biological missiles,” these sophisticated molecules represent a preciseRead More…
Antigen Target Selection A major challenge in developing antibody-drug conjugates (ADCs) for cancer lies in the identification and validation of sufficient antigen targets for the monoclonal antibody component. Several factors need toRead More…
Antibody-drug conjugates, often referred to as ADCs, are a type of dual-targeted therapeutic. They consist of three key components: an antibody, a payload, and a linker. The antibody determines the target disease,Read More…
In recent years, the development of antibody-drug conjugate (ADC) therapies has flourished, leading to significant advancements in treating solid tumors. The FDA has approved six solid tumor ADCs so far—Sacituzumab govitecan (SG),Read More…
So far, a total of 16 ADC drugs have been approved worldwide, and one (trastuzumab duocarmazine) is still in the stage of applying for listing. In recent years, with the significant increaseRead More…
In November 2022, ImmunoGen announced that the Food and Drug Administration (FDA) has accelerated the approval for Elahere (mirvetuximab soravtansine-gynx): a monotherapy for adult patients with epithelial ovarian, fallopian, and primary peritonealRead More…
Chemical modification of specific in situ antibody The natural structure of monoclonal antibodies provides a variety of possibilities for bioconjugation. The chemical-based, specific natural (non-engineered) antibody conjugation has some benefits in thatRead More…
Creative Biolabs, one of the industry-pioneering CROs holding specialties in bioconjugate, participated in the 13th Annual World ADC Summit last week and announced the successful accomplishment of its journey in San Diego.Read More…
Seattle Genetics and its partner, Astellas, have recently announced that the patients were selected for EV-201, the key phase II clinical trial of an experimental antibody-drug conjugate (ADC) called enfortumab vedotin. TheRead More…